ID   RAF1_HUMAN              Reviewed;         648 AA.
AC   P04049; B0LPH8; B2R5N3; Q15278; Q9UC20;
DT   01-NOV-1986, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1986, sequence version 1.
DT   12-OCT-2022, entry version 253.
DE   RecName: Full=RAF proto-oncogene serine/threonine-protein kinase {ECO:0000305};
DE            EC=2.7.11.1 {ECO:0000269|PubMed:17603483};
DE   AltName: Full=Proto-oncogene c-RAF;
DE            Short=cRaf;
DE   AltName: Full=Raf-1;
GN   Name=RAF1 {ECO:0000312|HGNC:HGNC:9829}; Synonyms=RAF;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=3003687; DOI=10.1093/nar/14.2.1009;
RA   Bonner T.I., Oppermann H., Seeburg P., Kerby S.B., Gunnell M.A.,
RA   Young A.C., Rapp U.R.;
RT   "The complete coding sequence of the human raf oncogene and the
RT   corresponding structure of the c-raf-1 gene.";
RL   Nucleic Acids Res. 14:1009-1015(1986).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT LEU-308.
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT LEU-308.
RG   NIEHS SNPs program;
RL   Submitted (DEC-2007) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Pancreas;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 228-648.
RX   PubMed=2993863; DOI=10.1128/mcb.5.6.1400-1407.1985;
RA   Bonner T.I., Kerby S.B., Sutrave P., Gunnell M.A., Mark G., Rapp U.R.;
RT   "Structure and biological activity of human homologs of the raf/mil
RT   oncogene.";
RL   Mol. Cell. Biol. 5:1400-1407(1985).
RN   [7]
RP   PROTEIN SEQUENCE OF 42-53; 60-65; 310-316 AND 564-572, INTERACTION WITH
RP   PRMT5, METHYLATION AT ARG-563, PHOSPHORYLATION AT SER-289; SER-296;
RP   SER-301; SER-338 AND SER-621, AND MUTAGENESIS OF ARG-563.
RX   PubMed=21917714; DOI=10.1126/scisignal.2001936;
RA   Andreu-Perez P., Esteve-Puig R., de Torre-Minguela C., Lopez-Fauqued M.,
RA   Bech-Serra J.J., Tenbaum S., Garcia-Trevijano E.R., Canals F., Merlino G.,
RA   Avila M.A., Recio J.A.;
RT   "Protein arginine methyltransferase 5 regulates ERK1/2 signal transduction
RT   amplitude and cell fate through CRAF.";
RL   Sci. Signal. 4:RA58-RA58(2011).
RN   [8]
RP   PROTEIN SEQUENCE OF 254-278, AND PHOSPHORYLATION AT THR-269.
RX   PubMed=7477354; DOI=10.1038/378307a0;
RA   Yao B., Zhang Y., Delikat S., Mathias S., Basu S., Kolesnick R.;
RT   "Phosphorylation of Raf by ceramide-activated protein kinase.";
RL   Nature 378:307-310(1995).
RN   [9]
RP   PARTIAL NUCLEOTIDE SEQUENCE [GENOMIC DNA], ALTERNATIVE SPLICING, AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Placenta;
RX   PubMed=1886707;
RA   Dozier C., Ansieau S., Ferreira E., Coll J., Stehelin D.;
RT   "An alternatively spliced c-mil/raf mRNA is predominantly expressed in
RT   chicken muscular tissues and conserved among vertebrate species.";
RL   Oncogene 6:1307-1311(1991).
RN   [10]
RP   PHOSPHORYLATION AT SER-43; SER-259; THR-268; SER-499 AND SER-621.
RX   PubMed=8349614; DOI=10.1016/s0021-9258(19)85336-x;
RA   Morrison D.K., Heidecker G., Rapp U.R., Copeland T.D.;
RT   "Identification of the major phosphorylation sites of the Raf-1 kinase.";
RL   J. Biol. Chem. 268:17309-17316(1993).
RN   [11]
RP   INTERACTION WITH YWHAZ, AND FUNCTION.
RX   PubMed=9360956; DOI=10.1074/jbc.272.46.28882;
RA   Dubois T., Rommel C., Howell S., Steinhussen U., Soneji Y., Morrice N.,
RA   Moelling K., Aitken A.;
RT   "14-3-3 is phosphorylated by casein kinase I on residue 233.
RT   Phosphorylation at this site in vivo regulates Raf/14-3-3 interaction.";
RL   J. Biol. Chem. 272:28882-28888(1997).
RN   [12]
RP   PHOSPHORYLATION.
RX   PubMed=9823899; DOI=10.1038/24184;
RA   King A.J., Sun H., Diaz B., Barnard D., Miao W., Bagrodia S.,
RA   Marshall M.S.;
RT   "The protein kinase Pak3 positively regulates Raf-1 activity through
RT   phosphorylation of serine 338.";
RL   Nature 396:180-183(1998).
RN   [13]
RP   ERRATUM OF PUBMED:9823899.
RA   King A.J., Sun H., Diaz B., Barnard D., Miao W., Bagrodia S.,
RA   Marshall M.S.;
RL   Nature 406:439-439(2000).
RN   [14]
RP   PHOSPHORYLATION AT SER-259 BY PKB/AKT1, ACTIVITY REGULATION, AND
RP   INTERACTION WITH PKB/AKT1.
RX   PubMed=10576742; DOI=10.1126/science.286.5445.1741;
RA   Zimmermann S., Moelling K.;
RT   "Phosphorylation and regulation of Raf by Akt (protein kinase B).";
RL   Science 286:1741-1744(1999).
RN   [15]
RP   PHOSPHORYLATION AT SER-259 AND SER-621, DEPHOSPHORYLATION AT SER-43;
RP   SER-259 AND SER-621, ACTIVITY REGULATION, AND INTERACTION WITH PPP2CA AND
RP   PPP2R1B.
RX   PubMed=10801873; DOI=10.1074/jbc.m003259200;
RA   Abraham D., Podar K., Pacher M., Kubicek M., Welzel N., Hemmings B.A.,
RA   Dilworth S.M., Mischak H., Kolch W., Baccarini M.;
RT   "Raf-1-associated protein phosphatase 2A as a positive regulator of kinase
RT   activation.";
RL   J. Biol. Chem. 275:22300-22304(2000).
RN   [16]
RP   ACTIVITY REGULATION, AND PHOSPHORYLATION AT THR-491 AND SER-494.
RX   PubMed=11447113; DOI=10.1093/emboj/20.14.3716;
RA   Chong H., Lee J., Guan K.L.;
RT   "Positive and negative regulation of Raf kinase activity and function by
RT   phosphorylation.";
RL   EMBO J. 20:3716-3727(2001).
RN   [17]
RP   FUNCTION, AND INTERACTION WITH MAP3K5/ASK1.
RX   PubMed=11427728; DOI=10.1073/pnas.141224398;
RA   Chen J., Fujii K., Zhang L., Roberts T., Fu H.;
RT   "Raf-1 promotes cell survival by antagonizing apoptosis signal-regulating
RT   kinase 1 through a MEK-ERK independent mechanism.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:7783-7788(2001).
RN   [18]
RP   FUNCTION IN PHOSPHORYLATION OF PPP1R12A, AND INTERACTION WITH PPP1R12A.
RX   PubMed=11719507; DOI=10.1074/jbc.m106343200;
RA   Broustas C.G., Grammatikakis N., Eto M., Dent P., Brautigan D.L., Kasid U.;
RT   "Phosphorylation of the myosin-binding subunit of myosin phosphatase by
RT   Raf-1 and inhibition of phosphatase activity.";
RL   J. Biol. Chem. 277:3053-3059(2002).
RN   [19]
RP   PHOSPHORYLATION AT SER-338 BY PAK1, ACTIVITY REGULATION, AND INTERACTION
RP   WITH PAK1.
RX   PubMed=11733498; DOI=10.1074/jbc.m110000200;
RA   Zang M., Hayne C., Luo Z.;
RT   "Interaction between active Pak1 and Raf-1 is necessary for phosphorylation
RT   and activation of Raf-1.";
RL   J. Biol. Chem. 277:4395-4405(2002).
RN   [20]
RP   PHOSPHORYLATION AT SER-259, DEPHOSPHORYLATION AT SER-259, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=11756411; DOI=10.1074/jbc.m108733200;
RA   Kubicek M., Pacher M., Abraham D., Podar K., Eulitz M., Baccarini M.;
RT   "Dephosphorylation of Ser-259 regulates Raf-1 membrane association.";
RL   J. Biol. Chem. 277:7913-7919(2002).
RN   [21]
RP   COMPETITION WITH RIN1.
RX   PubMed=11784866; DOI=10.1128/mcb.22.3.916-926.2001;
RA   Wang Y., Waldron R.T., Dhaka A., Patel A., Riley M.M., Rozengurt E.,
RA   Colicelli J.;
RT   "The RAS effector RIN1 directly competes with RAF and is regulated by 14-3-
RT   3 proteins.";
RL   Mol. Cell. Biol. 22:916-926(2002).
RN   [22]
RP   ACTIVITY REGULATION, AND INTERACTION WITH SPRY2 AND SPRY4.
RX   PubMed=12717443; DOI=10.1038/ncb978;
RA   Sasaki A., Taketomi T., Kato R., Saeki K., Nonami A., Sasaki M.,
RA   Kuriyama M., Saito N., Shibuya M., Yoshimura A.;
RT   "Mammalian Sprouty4 suppresses Ras-independent ERK activation by binding to
RT   Raf1.";
RL   Nat. Cell Biol. 5:427-432(2003).
RN   [23]
RP   PHOSPHORYLATION AT SER-259.
RX   PubMed=15047712; DOI=10.1074/jbc.m314192200;
RA   Kunapuli P., Kasyapa C.S., Hawthorn L., Cowell J.K.;
RT   "LGI1, a putative tumor metastasis suppressor gene, controls in vitro
RT   invasiveness and expression of matrix metalloproteinases in glioma cells
RT   through the ERK1/2 pathway.";
RL   J. Biol. Chem. 279:23151-23157(2004).
RN   [24]
RP   ERRATUM OF PUBMED:15047712.
RA   Kunapuli P., Kasyapa C.S., Hawthorn L., Cowell J.K.;
RL   J. Biol. Chem. 282:2752-2752(2007).
RN   [25]
RP   FUNCTION IN PHOSPHORYLATION OF ADCY2; ADCY5 AND ADCY6, AND INTERACTION WITH
RP   ADCY2; ADCY5 AND ADCY6.
RX   PubMed=15385642; DOI=10.1124/mol.66.4.921;
RA   Ding Q., Gros R., Gray I.D., Taussig R., Ferguson S.S., Feldman R.D.;
RT   "Raf kinase activation of adenylyl cyclases: isoform-selective
RT   regulation.";
RL   Mol. Pharmacol. 66:921-928(2004).
RN   [26]
RP   INTERACTION WITH STK3/MST2, AND FUNCTION.
RX   PubMed=15618521; DOI=10.1126/science.1103233;
RA   O'Neill E., Rushworth L., Baccarini M., Kolch W.;
RT   "Role of the kinase MST2 in suppression of apoptosis by the proto-oncogene
RT   product Raf-1.";
RL   Science 306:2267-2270(2004).
RN   [27]
RP   INTERACTION WITH RCAN1/DSCR1.
RX   PubMed=15935327; DOI=10.1016/j.abb.2005.05.002;
RA   Cho Y.J., Abe M., Kim S.Y., Sato Y.;
RT   "Raf-1 is a binding partner of DSCR1.";
RL   Arch. Biochem. Biophys. 439:121-128(2005).
RN   [28]
RP   REVIEW ON FUNCTION.
RX   PubMed=15943972; DOI=10.1016/j.febslet.2005.03.024;
RA   Baccarini M.;
RT   "Second nature: biological functions of the Raf-1 'kinase'.";
RL   FEBS Lett. 579:3271-3277(2005).
RN   [29]
RP   FUNCTION IN PHOSPHORYLATION OF BAD, PHOSPHORYLATION AT SER-338 AND SER-339
RP   BY PAK1, SUBCELLULAR LOCATION, AND INTERACTION WITH BCL2.
RX   PubMed=15849194; DOI=10.1074/jbc.m413374200;
RA   Jin S., Zhuo Y., Guo W., Field J.;
RT   "p21-activated Kinase 1 (Pak1)-dependent phosphorylation of Raf-1 regulates
RT   its mitochondrial localization, phosphorylation of BAD, and Bcl-2
RT   association.";
RL   J. Biol. Chem. 280:24698-24705(2005).
RN   [30]
RP   PHOSPHORYLATION AT SER-471.
RX   PubMed=16093354; DOI=10.1091/mbc.e05-02-0090;
RA   Zhu J., Balan V., Bronisz A., Balan K., Sun H., Leicht D.T., Luo Z.,
RA   Qin J., Avruch J., Tzivion G.;
RT   "Identification of Raf-1 S471 as a novel phosphorylation site critical for
RT   Raf-1 and B-Raf kinase activities and for MEK binding.";
RL   Mol. Biol. Cell 16:4733-4744(2005).
RN   [31]
RP   IDENTIFICATION IN A COMPLEX WITH PP1CA; PPP1CB; PPP1CC; SHOC2 AND MRAS,
RP   PHOSPHORYLATION AT SER-259, AND CHARACTERIZATION OF VARIANT ALA-259.
RX   PubMed=16630891; DOI=10.1016/j.molcel.2006.03.027;
RA   Rodriguez-Viciana P., Oses-Prieto J., Burlingame A., Fried M.,
RA   McCormick F.;
RT   "A phosphatase holoenzyme comprised of Shoc2/Sur8 and the catalytic subunit
RT   of PP1 functions as an M-Ras effector to modulate Raf activity.";
RL   Mol. Cell 22:217-230(2006).
RN   [32]
RP   SUBUNIT.
RX   PubMed=16508002; DOI=10.1128/mcb.26.6.2262-2272.2006;
RA   Rushworth L.K., Hindley A.D., O'Neill E., Kolch W.;
RT   "Regulation and role of Raf-1/B-Raf heterodimerization.";
RL   Mol. Cell. Biol. 26:2262-2272(2006).
RN   [33]
RP   FUNCTION AS KINASE, ACTIVITY REGULATION, PHOSPHORYLATION AT SER-259;
RP   SER-338; TYR-340; TYR-341 AND SER-621, DEPHOSPHORYLATION AT SER-338 BY
RP   PPP5C, AND MUTAGENESIS OF 338-SER-SER-339; 340-TYR-TYR-341; THR-491 AND
RP   SER-494.
RX   PubMed=16892053; DOI=10.1038/ncb1465;
RA   von Kriegsheim A., Pitt A., Grindlay G.J., Kolch W., Dhillon A.S.;
RT   "Regulation of the Raf-MEK-ERK pathway by protein phosphatase 5.";
RL   Nat. Cell Biol. 8:1011-1016(2006).
RN   [34]
RP   REVIEW ON REGULATION.
RX   PubMed=17218791; DOI=10.4161/cc.6.1.3593;
RA   Dhillon A.S., von Kriegsheim A., Grindlay J., Kolch W.;
RT   "Phosphatase and feedback regulation of Raf-1 signaling.";
RL   Cell Cycle 6:3-7(2007).
RN   [35]
RP   FUNCTION.
RX   PubMed=16924233; DOI=10.1038/sj.onc.1209902;
RA   Wang Z., Wade P., Mandell K.J., Akyildiz A., Parkos C.A., Mrsny R.J.,
RA   Nusrat A.;
RT   "Raf 1 represses expression of the tight junction protein occludin via
RT   activation of the zinc-finger transcription factor slug.";
RL   Oncogene 26:1222-1230(2007).
RN   [36]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-252, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic kidney;
RX   PubMed=17525332; DOI=10.1126/science.1140321;
RA   Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III, Hurov K.E.,
RA   Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y.,
RA   Gygi S.P., Elledge S.J.;
RT   "ATM and ATR substrate analysis reveals extensive protein networks
RT   responsive to DNA damage.";
RL   Science 316:1160-1166(2007).
RN   [37]
RP   ACTIVITY REGULATION, AND INTERACTION WITH PEBP1/RKIP.
RX   PubMed=18294816; DOI=10.1016/j.cellsig.2008.01.012;
RA   Rath O., Park S., Tang H.H., Banfield M.J., Brady R.L., Lee Y.C.,
RA   Dignam J.D., Sedivy J.M., Kolch W., Yeung K.C.;
RT   "The RKIP (Raf-1 Kinase Inhibitor Protein) conserved pocket binds to the
RT   phosphorylated N-region of Raf-1 and inhibits the Raf-1-mediated activated
RT   phosphorylation of MEK.";
RL   Cell. Signal. 20:935-941(2008).
RN   [38]
RP   PHOSPHORYLATION AT SER-338 BY PAK5.
RX   PubMed=18465753; DOI=10.1002/jcb.21809;
RA   Wu X., Carr H.S., Dan I., Ruvolo P.P., Frost J.A.;
RT   "p21 activated kinase 5 activates Raf-1 and targets it to mitochondria.";
RL   J. Cell. Biochem. 105:167-175(2008).
RN   [39]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient
RT   phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [40]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [41]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-642, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [42]
RP   SUBCELLULAR LOCATION.
RX   PubMed=19298812; DOI=10.1016/j.yexcr.2009.03.004;
RA   Smith J., Bunaciu R.P., Reiterer G., Coder D., George T., Asaly M., Yen A.;
RT   "Retinoic acid induces nuclear accumulation of Raf1 during differentiation
RT   of HL-60 cells.";
RL   Exp. Cell Res. 315:2241-2248(2009).
RN   [43]
RP   ACTIVITY REGULATION, SUBUNIT, SUBCELLULAR LOCATION, AND INTERACTION WITH
RP   DGKH.
RX   PubMed=19710016; DOI=10.1074/jbc.m109.043604;
RA   Yasuda S., Kai M., Imai S., Takeishi K., Taketomi A., Toyota M., Kanoh H.,
RA   Sakane F.;
RT   "Diacylglycerol kinase eta augments C-Raf activity and B-Raf/C-Raf
RT   heterodimerization.";
RL   J. Biol. Chem. 284:29559-29570(2009).
RN   [44]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-289 AND SER-301, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [45]
RP   REVIEW.
RX   PubMed=20674547; DOI=10.1016/j.bbrc.2010.07.092;
RA   Roskoski R. Jr.;
RT   "RAF protein-serine/threonine kinases: structure and regulation.";
RL   Biochem. Biophys. Res. Commun. 399:313-317(2010).
RN   [46]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [47]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [48]
RP   REVIEW.
RX   PubMed=21779496; DOI=10.1177/1947601911407323;
RA   Matallanas D., Birtwistle M., Romano D., Zebisch A., Rauch J.,
RA   von Kriegsheim A., Kolch W.;
RT   "Raf family kinases: old dogs have learned new tricks.";
RL   Genes Cancer 2:232-260(2011).
RN   [49]
RP   MUTAGENESIS OF LYS-375, AND INTERACTION WITH NEK10 AND MAP2K1.
RX   PubMed=20956560; DOI=10.1128/mcb.00648-10;
RA   Moniz L.S., Stambolic V.;
RT   "Nek10 mediates G2/M cell cycle arrest and MEK autoactivation in response
RT   to UV irradiation.";
RL   Mol. Cell. Biol. 31:30-42(2011).
RN   [50]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [51]
RP   INTERACTION WITH FAM83B.
RX   PubMed=22886302; DOI=10.1172/jci60517;
RA   Cipriano R., Graham J., Miskimen K.L., Bryson B.L., Bruntz R.C.,
RA   Scott S.A., Brown H.A., Stark G.R., Jackson M.W.;
RT   "FAM83B mediates EGFR- and RAS-driven oncogenic transformation.";
RL   J. Clin. Invest. 122:3197-3210(2012).
RN   [52]
RP   INTERACTION WITH GLS.
RX   PubMed=22538822; DOI=10.1073/pnas.1116573109;
RA   Thangavelu K., Pan C.Q., Karlberg T., Balaji G., Uttamchandani M.,
RA   Suresh V., Schuler H., Low B.C., Sivaraman J.;
RT   "Structural basis for the allosteric inhibitory mechanism of human kidney-
RT   type glutaminase (KGA) and its regulation by Raf-Mek-Erk signaling in
RT   cancer cell metabolism.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:7705-7710(2012).
RN   [53]
RP   INTERACTION WITH MFHAS1.
RX   PubMed=23327923; DOI=10.1182/blood-2011-10-385252;
RA   Kumkhaek C., Aerbajinai W., Liu W., Zhu J., Uchida N., Kurlander R.,
RA   Hsieh M.M., Tisdale J.F., Rodgers G.P.;
RT   "MASL1 induces erythroid differentiation in human erythropoietin-dependent
RT   CD34+ cells through the Raf/MEK/ERK pathway.";
RL   Blood 121:3216-3227(2013).
RN   [54]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-296; SER-301 AND SER-642, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [55]
RP   INTERACTION WITH PDE8A.
RX   PubMed=23509299; DOI=10.1073/pnas.1303004110;
RA   Brown K.M., Day J.P., Huston E., Zimmermann B., Hampel K., Christian F.,
RA   Romano D., Terhzaz S., Lee L.C., Willis M.J., Morton D.B., Beavo J.A.,
RA   Shimizu-Albergine M., Davies S.A., Kolch W., Houslay M.D., Baillie G.S.;
RT   "Phosphodiesterase-8A binds to and regulates Raf-1 kinase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 110:E1533-E1542(2013).
RN   [56]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [57]
RP   IDENTIFICATION IN A COMPLEX WITH HSP90; HSP70; CDC37; PPP5C; TSC1; TSC2;
RP   AKT; CDK4 AND NR3C1.
RX   PubMed=29127155; DOI=10.15252/embj.201796700;
RA   Woodford M.R., Sager R.A., Marris E., Dunn D.M., Blanden A.R., Murphy R.L.,
RA   Rensing N., Shapiro O., Panaretou B., Prodromou C., Loh S.N., Gutmann D.H.,
RA   Bourboulia D., Bratslavsky G., Wong M., Mollapour M.;
RT   "Tumor suppressor Tsc1 is a new Hsp90 co-chaperone that facilitates folding
RT   of kinase and non-kinase clients.";
RL   EMBO J. 36:3650-3665(2017).
RN   [58]
RP   INTERACTION WITH LZTR1.
RX   PubMed=30368668; DOI=10.1007/s00439-018-1951-7;
RA   Umeki I., Niihori T., Abe T., Kanno S.I., Okamoto N., Mizuno S.,
RA   Kurosawa K., Nagasaki K., Yoshida M., Ohashi H., Inoue S.I., Matsubara Y.,
RA   Fujiwara I., Kure S., Aoki Y.;
RT   "Delineation of LZTR1 mutation-positive patients with Noonan syndrome and
RT   identification of LZTR1 binding to RAF1-PPP1CB complexes.";
RL   Hum. Genet. 138:21-35(2019).
RN   [59]
RP   INTERACTION WITH YWHAZ.
RX   PubMed=31024343; DOI=10.3389/fphys.2019.00388;
RA   Popov I.K., Hiatt S.M., Whalen S., Keren B., Ruivenkamp C.,
RA   van Haeringen A., Chen M.J., Cooper G.M., Korf B.R., Chang C.;
RT   "A YWHAZ variant associated with cardiofaciocutaneous syndrome activates
RT   the RAF-ERK pathway.";
RL   Front. Physiol. 10:388-388(2019).
RN   [60]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 51-131.
RX   PubMed=7791872; DOI=10.1038/375554a0;
RA   Nassar N., Horn G., Herrmann C., Scherer A., McCormick F., Wittinghofer A.;
RT   "The 2.2 A crystal structure of the Ras-binding domain of the
RT   serine/threonine kinase c-Raf1 in complex with Rap1A and a GTP analogue.";
RL   Nature 375:554-560(1995).
RN   [61]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 56-131.
RX   PubMed=8756332; DOI=10.1038/nsb0896-723;
RA   Nassar N., Horn G., Herrmann C., Block C., Janknecht R., Wittinghofer A.;
RT   "Ras/Rap effector specificity determined by charge reversal.";
RL   Nat. Struct. Biol. 3:723-729(1996).
RN   [62]
RP   STRUCTURE BY NMR OF 55-132.
RX   PubMed=7766599; DOI=10.1021/bi00021a001;
RA   Emerson S.D., Madison V.S., Palermo R.E., Waugh D.S., Scheffler J.E.,
RA   Tsao K.L., Kiefer S.E., Liu S.P., Fry D.C.;
RT   "Solution structure of the Ras-binding domain of c-Raf-1 and identification
RT   of its Ras interaction surface.";
RL   Biochemistry 34:6911-6918(1995).
RN   [63]
RP   STRUCTURE BY NMR OF 136-187.
RX   PubMed=8710867; DOI=10.1073/pnas.93.16.8312;
RA   Mott H.R., Carpenter J.W., Zhong S., Ghosh S., Bell R.M., Campbell S.L.;
RT   "The solution structure of the Raf-1 cysteine-rich domain: a novel ras and
RT   phospholipid binding site.";
RL   Proc. Natl. Acad. Sci. U.S.A. 93:8312-8317(1996).
RN   [64]
RP   VARIANTS NS5 SER-256; PHE-259; ARG-260; LEU-261; SER-261; ASN-486; GLY-486;
RP   ILE-491; ARG-491 AND THR-612, VARIANT HYPERTROPHIC CARDIOMYOPATHY ILE-260,
RP   VARIANTS LPRD2 LEU-257 AND VAL-613, VARIANT NS5 LEU-257, CHARACTERIZATION
RP   OF VARIANTS NS5 SER-261; ASN-486 AND ILE-491, CHARACTERIZATION OF VARIANT
RP   LPRD2 VAL-613, AND CATALYTIC ACTIVITY.
RX   PubMed=17603483; DOI=10.1038/ng2073;
RA   Pandit B., Sarkozy A., Pennacchio L.A., Carta C., Oishi K., Martinelli S.,
RA   Pogna E.A., Schackwitz W., Ustaszewska A., Landstrom A., Bos J.M.,
RA   Ommen S.R., Esposito G., Lepri F., Faul C., Mundel P., Lopez Siguero J.P.,
RA   Tenconi R., Selicorni A., Rossi C., Mazzanti L., Torrente I., Marino B.,
RA   Digilio M.C., Zampino G., Ackerman M.J., Dallapiccola B., Tartaglia M.,
RA   Gelb B.D.;
RT   "Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with
RT   hypertrophic cardiomyopathy.";
RL   Nat. Genet. 39:1007-1012(2007).
RN   [65]
RP   VARIANTS NS5 LEU-257; ALA-261; SER-261; ALA-263 AND VAL-613, AND
RP   CHARACTERIZATION OF VARIANTS NS5 LEU-257; ALA-261; SER-261; ALA-263 AND
RP   VAL-613.
RX   PubMed=17603482; DOI=10.1038/ng2078;
RA   Razzaque M.A., Nishizawa T., Komoike Y., Yagi H., Furutani M., Amo R.,
RA   Kamisago M., Momma K., Katayama H., Nakagawa M., Fujiwara Y.,
RA   Matsushima M., Mizuno K., Tokuyama M., Hirota H., Muneuchi J.,
RA   Higashinakagawa T., Matsuoka R.;
RT   "Germline gain-of-function mutations in RAF1 cause Noonan syndrome.";
RL   Nat. Genet. 39:1013-1017(2007).
RN   [66]
RP   VARIANTS [LARGE SCALE ANALYSIS] ALA-259 AND HIS-335.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [67]
RP   VARIANT NS5 SER-261.
RX   PubMed=20683980; DOI=10.1002/ajmg.a.33564;
RA   Longoni M., Moncini S., Cisternino M., Morella I.M., Ferraiuolo S.,
RA   Russo S., Mannarino S., Brazzelli V., Coi P., Zippel R., Venturin M.,
RA   Riva P.;
RT   "Noonan syndrome associated with both a new Jnk-activating familial SOS1
RT   and a de novo RAF1 mutations.";
RL   Am. J. Med. Genet. A 152:2176-2184(2010).
RN   [68]
RP   INVOLVEMENT IN CMD1NN, VARIANTS CMD1NN THR-237; ALA-310; ALA-332; PRO-603;
RP   ARG-626 AND MET-641, AND CHARACTERIZATION OF VARIANTS CMD1NN THR-237;
RP   ALA-310; ALA-332; PRO-603; ARG-626 AND MET-641.
RX   PubMed=24777450; DOI=10.1038/ng.2963;
RA   Dhandapany P.S., Razzaque M.A., Muthusami U., Kunnoth S., Edwards J.J.,
RA   Mulero-Navarro S., Riess I., Pardo S., Sheng J., Rani D.S., Rani B.,
RA   Govindaraj P., Flex E., Yokota T., Furutani M., Nishizawa T., Nakanishi T.,
RA   Robbins J., Limongelli G., Hajjar R.J., Lebeche D., Bahl A., Khullar M.,
RA   Rathinavel A., Sadler K.C., Tartaglia M., Matsuoka R., Thangaraj K.,
RA   Gelb B.D.;
RT   "RAF1 mutations in childhood-onset dilated cardiomyopathy.";
RL   Nat. Genet. 46:635-639(2014).
CC   -!- FUNCTION: Serine/threonine-protein kinase that acts as a regulatory
CC       link between the membrane-associated Ras GTPases and the MAPK/ERK
CC       cascade, and this critical regulatory link functions as a switch
CC       determining cell fate decisions including proliferation,
CC       differentiation, apoptosis, survival and oncogenic transformation. RAF1
CC       activation initiates a mitogen-activated protein kinase (MAPK) cascade
CC       that comprises a sequential phosphorylation of the dual-specific MAPK
CC       kinases (MAP2K1/MEK1 and MAP2K2/MEK2) and the extracellular signal-
CC       regulated kinases (MAPK3/ERK1 and MAPK1/ERK2). The phosphorylated form
CC       of RAF1 (on residues Ser-338 and Ser-339, by PAK1) phosphorylates
CC       BAD/Bcl2-antagonist of cell death at 'Ser-75'. Phosphorylates adenylyl
CC       cyclases: ADCY2, ADCY5 and ADCY6, resulting in their activation.
CC       Phosphorylates PPP1R12A resulting in inhibition of the phosphatase
CC       activity. Phosphorylates TNNT2/cardiac muscle troponin T. Can promote
CC       NF-kB activation and inhibit signal transducers involved in motility
CC       (ROCK2), apoptosis (MAP3K5/ASK1 and STK3/MST2), proliferation and
CC       angiogenesis (RB1). Can protect cells from apoptosis also by
CC       translocating to the mitochondria where it binds BCL2 and displaces
CC       BAD/Bcl2-antagonist of cell death. Regulates Rho signaling and
CC       migration, and is required for normal wound healing. Plays a role in
CC       the oncogenic transformation of epithelial cells via repression of the
CC       TJ protein, occludin (OCLN) by inducing the up-regulation of a
CC       transcriptional repressor SNAI2/SLUG, which induces down-regulation of
CC       OCLN. Restricts caspase activation in response to selected stimuli,
CC       notably Fas stimulation, pathogen-mediated macrophage apoptosis, and
CC       erythroid differentiation. {ECO:0000269|PubMed:11427728,
CC       ECO:0000269|PubMed:11719507, ECO:0000269|PubMed:15385642,
CC       ECO:0000269|PubMed:15618521, ECO:0000269|PubMed:15849194,
CC       ECO:0000269|PubMed:16892053, ECO:0000269|PubMed:16924233,
CC       ECO:0000269|PubMed:9360956}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC         Evidence={ECO:0000269|PubMed:17603483};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:17990;
CC         Evidence={ECO:0000269|PubMed:17603483};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.1; Evidence={ECO:0000269|PubMed:17603483};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:46609;
CC         Evidence={ECO:0000269|PubMed:17603483};
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC       Note=Binds 2 Zn(2+) ions per subunit.;
CC   -!- ACTIVITY REGULATION: Regulation is a highly complex process involving
CC       membrane recruitment, protein-protein interactions, dimerization, and
CC       phosphorylation/dephosphorylation events. Ras-GTP recruits RAF1 to the
CC       membrane, thereby promoting its activation. The inactive conformation
CC       of RAF1 is maintained by autoinhibitory interactions occurring between
CC       the N-terminal regulatory and the C-terminal catalytic domains and by
CC       the binding of a 14-3-3 protein that contacts two phosphorylation
CC       sites, Ser-259 and Ser-621. Upon mitogenic stimulation, Ras and PPP2R1A
CC       cooperate to release autoinhibition and the subsequent phosphorylation
CC       of activating sites: Ser-338, Tyr-341, Thr-491, and Ser-494, yields a
CC       fully active kinase. Through a negative feedback mechanism involving
CC       MAPK1/ERK2, RAF1 is phosphorylated on Ser-29, Ser-43, Ser-289, Ser-296,
CC       Ser-301 and Ser-642 by MAPK1/ERK2, which yields an inactive,
CC       desensitized kinase. The signaling-competent conformation of RAF1 is
CC       finally re-established by the coordinated action of PIN1, a prolyl
CC       isomerase that converts pSer and pThr residues from the cis to the
CC       trans conformation, which is preferentially recognized and
CC       dephosphorylated by PPP2R1A. Activated by homodimerization and
CC       heterodimerization (with BRAF). Also regulated through association with
CC       other proteins such as KSR2, CNKSR1/CNK1, PEBP1/RKIP, PHB/prohibitin
CC       and SPRY4. PEBP1/RKIP acts by dissociating RAF1 from its substrates
CC       MAP2K1/MEK1 and MAP2K2/MEK2. PHB/prohibitin facilitates the
CC       displacement of 14-3-3 from RAF1 by activated Ras, thereby promoting
CC       cell membrane localization and phosphorylation of RAF1 at the
CC       activating Ser-338. SPRY4 inhibits Ras-independent, but not Ras-
CC       dependent, activation of RAF1. CNKSR1/CNK1 regulates Src-mediated RAF1
CC       activation. {ECO:0000269|PubMed:10576742, ECO:0000269|PubMed:10801873,
CC       ECO:0000269|PubMed:11447113, ECO:0000269|PubMed:11733498,
CC       ECO:0000269|PubMed:12717443, ECO:0000269|PubMed:16892053,
CC       ECO:0000269|PubMed:18294816, ECO:0000269|PubMed:19710016}.
CC   -!- SUBUNIT: Monomer. Homodimer. Heterodimerizes with BRAF and this
CC       heterodimer possesses a highly increased kinase activity compared to
CC       the respective homodimers or monomers (PubMed:16508002).
CC       Heterodimerization is mitogen-regulated and enhanced by 14-3-3 proteins
CC       (PubMed:16508002). MAPK1/ERK2 activation can induce a negative feedback
CC       that promotes the dissociation of the heterodimer (PubMed:16508002).
CC       Forms a multiprotein complex with Ras (M-Ras/MRAS), SHOC2 and protein
CC       phosphatase 1 (PPP1CA, PPP1CB and PPP1CC) (PubMed:16630891). Interacts
CC       with LZTR1 (PubMed:30368668). Interacts with Ras proteins; the
CC       interaction is antagonized by RIN1 (PubMed:11784866). Weakly interacts
CC       with RIT1. Interacts (via N-terminus) with RGS14 (via RBD domains); the
CC       interaction mediates the formation of a ternary complex with BRAF, a
CC       ternary complex inhibited by GNAI1 (By similarity). Probably forms a
CC       complex composed of chaperones HSP90 and HSP70, co-chaperones CDC37,
CC       PPP5C, TSC1 and client protein TSC2, CDK4, AKT, RAF1 and NR3C1; this
CC       complex does not contain co-chaperones STIP1/HOP and PTGES3/p23
CC       (PubMed:29127155). Interacts with STK3/MST2; the interaction inhibits
CC       its pro-apoptotic activity (PubMed:15618521). Interacts (when
CC       phosphorylated at Ser-259) with YWHAZ (unphosphorylated at 'Thr-232')
CC       (PubMed:9360956, PubMed:31024343). Interacts with MAP2K1/MEK1 and
CC       MAP2K2/MEK2 (By similarity). Interacts with MAP3K5/ASF1 (via N-
CC       terminus) and this interaction inhibits the proapoptotic function of
CC       MAP3K5/ASK1 (PubMed:11427728). Interacts with PAK1 (via kinase domain)
CC       (PubMed:11733498). The phosphorylated form interacts with PIN1 (By
CC       similarity). The Ser-338 and Ser-339 phosphorylated form (by PAK1)
CC       interacts with BCL2 (PubMed:15849194). Interacts with PEBP1/RKIP and
CC       this interaction is enhanced if RAF1 is phosphorylated on residues Ser-
CC       338, Ser-339, Tyr-340 and Tyr-341 (PubMed:18294816). Interacts with
CC       ADCY2, ADCY5, ADCY6, DGKH, RCAN1/DSCR1, PPP1R12A, PKB/AKT1, PPP2CA,
CC       PPP2R1B, SPRY2, SPRY4, CNKSR1/CNK1, KSR2 and PHB/prohibitin
CC       (PubMed:10801873, PubMed:11719507, PubMed:12717443, PubMed:15385642,
CC       PubMed:15935327, PubMed:19710016, PubMed:10576742). Interacts with
CC       ROCK2 (By similarity). In its active form, interacts with PRMT5
CC       (PubMed:21917714). Interacts with FAM83B; displaces 14-3-3 proteins
CC       from RAF1 and activates RAF1 (PubMed:22886302). Interacts with PDE8A;
CC       the interaction promotes RAF1 activity (PubMed:23509299). Interacts
CC       with MFHAS1 (PubMed:23327923). Interacts with GLS (PubMed:22538822).
CC       Interacts with NEK10 and MAP2K1; the interaction is direct with NEK10
CC       and required for ERK1/2-signaling pathway activation in response to UV
CC       irradiation (PubMed:20956560). {ECO:0000250|UniProtKB:P11345,
CC       ECO:0000250|UniProtKB:Q99N57, ECO:0000269|PubMed:10576742,
CC       ECO:0000269|PubMed:10801873, ECO:0000269|PubMed:11427728,
CC       ECO:0000269|PubMed:11719507, ECO:0000269|PubMed:11733498,
CC       ECO:0000269|PubMed:11784866, ECO:0000269|PubMed:12717443,
CC       ECO:0000269|PubMed:15385642, ECO:0000269|PubMed:15618521,
CC       ECO:0000269|PubMed:15849194, ECO:0000269|PubMed:15935327,
CC       ECO:0000269|PubMed:16508002, ECO:0000269|PubMed:16630891,
CC       ECO:0000269|PubMed:18294816, ECO:0000269|PubMed:19710016,
CC       ECO:0000269|PubMed:20956560, ECO:0000269|PubMed:21917714,
CC       ECO:0000269|PubMed:22538822, ECO:0000269|PubMed:22886302,
CC       ECO:0000269|PubMed:23327923, ECO:0000269|PubMed:23509299,
CC       ECO:0000269|PubMed:29127155, ECO:0000269|PubMed:30368668,
CC       ECO:0000269|PubMed:9360956}.
CC   -!- INTERACTION:
CC       P04049; P05067: APP; NbExp=3; IntAct=EBI-365996, EBI-77613;
CC       P04049; O95816: BAG2; NbExp=3; IntAct=EBI-365996, EBI-355275;
CC       P04049; P15056: BRAF; NbExp=57; IntAct=EBI-365996, EBI-365980;
CC       P04049; Q14790: CASP8; NbExp=3; IntAct=EBI-365996, EBI-78060;
CC       P04049; P49368: CCT3; NbExp=5; IntAct=EBI-365996, EBI-356673;
CC       P04049; P30304: CDC25A; NbExp=4; IntAct=EBI-365996, EBI-747671;
CC       P04049; Q16543: CDC37; NbExp=7; IntAct=EBI-365996, EBI-295634;
CC       P04049; P31327: CPS1; NbExp=4; IntAct=EBI-365996, EBI-536811;
CC       P04049; P01112: HRAS; NbExp=25; IntAct=EBI-365996, EBI-350145;
CC       P04049; P07900: HSP90AA1; NbExp=4; IntAct=EBI-365996, EBI-296047;
CC       P04049; P08238: HSP90AB1; NbExp=6; IntAct=EBI-365996, EBI-352572;
CC       P04049; P11021: HSPA5; NbExp=5; IntAct=EBI-365996, EBI-354921;
CC       P04049; P01116: KRAS; NbExp=6; IntAct=EBI-365996, EBI-367415;
CC       P04049; P01116-2: KRAS; NbExp=3; IntAct=EBI-365996, EBI-367427;
CC       P04049; Q02750: MAP2K1; NbExp=38; IntAct=EBI-365996, EBI-492564;
CC       P04049; P36507: MAP2K2; NbExp=6; IntAct=EBI-365996, EBI-1056930;
CC       P04049; Q12968: NFATC3; NbExp=2; IntAct=EBI-365996, EBI-5278441;
CC       P04049; P01111: NRAS; NbExp=9; IntAct=EBI-365996, EBI-721993;
CC       P04049; O43482: OIP5; NbExp=4; IntAct=EBI-365996, EBI-536879;
CC       P04049; Q13177: PAK2; NbExp=2; IntAct=EBI-365996, EBI-1045887;
CC       P04049; Q6TCH7: PAQR3; NbExp=3; IntAct=EBI-365996, EBI-15654365;
CC       P04049; P30086: PEBP1; NbExp=10; IntAct=EBI-365996, EBI-716384;
CC       P04049; Q96S96: PEBP4; NbExp=4; IntAct=EBI-365996, EBI-8563667;
CC       P04049; Q13526: PIN1; NbExp=2; IntAct=EBI-365996, EBI-714158;
CC       P04049; P14618: PKM; NbExp=3; IntAct=EBI-365996, EBI-353408;
CC       P04049; P67775: PPP2CA; NbExp=2; IntAct=EBI-365996, EBI-712311;
CC       P04049; Q13362: PPP2R5C; NbExp=2; IntAct=EBI-365996, EBI-1266156;
CC       P04049; P04049: RAF1; NbExp=6; IntAct=EBI-365996, EBI-365996;
CC       P04049; P62834: RAP1A; NbExp=2; IntAct=EBI-365996, EBI-491414;
CC       P04049; P06400: RB1; NbExp=3; IntAct=EBI-365996, EBI-491274;
CC       P04049; P53805-2: RCAN1; NbExp=4; IntAct=EBI-365996, EBI-1541912;
CC       P04049; P31947: SFN; NbExp=6; IntAct=EBI-365996, EBI-476295;
CC       P04049; Q13188: STK3; NbExp=6; IntAct=EBI-365996, EBI-992580;
CC       P04049; Q3ZCQ8: TIMM50; NbExp=6; IntAct=EBI-365996, EBI-355175;
CC       P04049; P31946: YWHAB; NbExp=21; IntAct=EBI-365996, EBI-359815;
CC       P04049; P62258: YWHAE; NbExp=6; IntAct=EBI-365996, EBI-356498;
CC       P04049; P61981: YWHAG; NbExp=6; IntAct=EBI-365996, EBI-359832;
CC       P04049; Q04917: YWHAH; NbExp=10; IntAct=EBI-365996, EBI-306940;
CC       P04049; P27348: YWHAQ; NbExp=7; IntAct=EBI-365996, EBI-359854;
CC       P04049; P63104: YWHAZ; NbExp=16; IntAct=EBI-365996, EBI-347088;
CC       P04049; P32883: Kras; Xeno; NbExp=2; IntAct=EBI-365996, EBI-644267;
CC       P04049; P28301: Lox; Xeno; NbExp=2; IntAct=EBI-365996, EBI-642911;
CC       P04049; Q9ESN9-2: Mapk8ip3; Xeno; NbExp=2; IntAct=EBI-365996, EBI-9549291;
CC       P04049; P03495: NS; Xeno; NbExp=2; IntAct=EBI-365996, EBI-2548993;
CC       P04049; O39474: NS5A; Xeno; NbExp=4; IntAct=EBI-365996, EBI-7016711;
CC       P04049; P01120: RAS2; Xeno; NbExp=2; IntAct=EBI-365996, EBI-14838;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Cell membrane. Mitochondrion. Nucleus.
CC       Note=Colocalizes with RGS14 and BRAF in both the cytoplasm and
CC       membranes. Phosphorylation at Ser-259 impairs its membrane
CC       accumulation. Recruited to the cell membrane by the active Ras protein.
CC       Phosphorylation at Ser-338 and Ser-339 by PAK1 is required for its
CC       mitochondrial localization. Retinoic acid-induced Ser-621
CC       phosphorylated form of RAF1 is predominantly localized at the nucleus.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1; Synonyms=6C;
CC         IsoId=P04049-1; Sequence=Displayed;
CC       Name=2; Synonyms=1A;
CC         IsoId=P04049-2; Sequence=VSP_034649;
CC   -!- TISSUE SPECIFICITY: In skeletal muscle, isoform 1 is more abundant than
CC       isoform 2. {ECO:0000269|PubMed:1886707}.
CC   -!- PTM: Phosphorylation at Thr-269, Ser-338, Tyr-341, Thr-491 and Ser-494
CC       results in its activation. Phosphorylation at Ser-29, Ser-43, Ser-289,
CC       Ser-296, Ser-301 and Ser-642 by MAPK1/ERK2 results in its inactivation.
CC       Phosphorylation at Ser-259 induces the interaction with YWHAZ and
CC       inactivates kinase activity. Dephosphorylation of Ser-259 by the
CC       complex containing protein phosphatase 1, SHOC2 and M-Ras/MRAS relieves
CC       inactivation, leading to stimulate RAF1 activity. Phosphorylation at
CC       Ser-338 by PAK1 and PAK5 and Ser-339 by PAK1 is required for its
CC       mitochondrial localization. Phosphorylation at Ser-621 in response to
CC       growth factor treatment stabilizes the protein, possibly by preventing
CC       proteasomal degradation. Phosphorylation at Ser-289, Ser-296, Ser-301,
CC       Ser-338 and Ser-621 are somehow linked to the methylation potential of
CC       cells. Treatment of cells with HGF in the presence of the methylation
CC       inhibitor 5'-methylthioadenosine (MTA) results in increased
CC       phosphorylation at Ser-338 and Ser-621 and decreased phosphorylation at
CC       Ser-296, Ser-301 and Ser-338. Dephosphorylation at Ser-338 by PPP5C
CC       results in an activity decrease. {ECO:0000269|PubMed:10576742,
CC       ECO:0000269|PubMed:10801873, ECO:0000269|PubMed:11447113,
CC       ECO:0000269|PubMed:11733498, ECO:0000269|PubMed:11756411,
CC       ECO:0000269|PubMed:15047712, ECO:0000269|PubMed:15849194,
CC       ECO:0000269|PubMed:16093354, ECO:0000269|PubMed:16630891,
CC       ECO:0000269|PubMed:16892053, ECO:0000269|PubMed:18465753,
CC       ECO:0000269|PubMed:21917714, ECO:0000269|PubMed:7477354,
CC       ECO:0000269|PubMed:8349614, ECO:0000269|PubMed:9823899}.
CC   -!- PTM: Methylated at Arg-563 in response to EGF treatment. This
CC       modification leads to destabilization of the protein, possibly through
CC       proteasomal degradation. {ECO:0000269|PubMed:21917714}.
CC   -!- DISEASE: Noonan syndrome 5 (NS5) [MIM:611553]: A form of Noonan
CC       syndrome, a disease characterized by short stature, facial dysmorphic
CC       features such as hypertelorism, a downward eyeslant and low-set
CC       posteriorly rotated ears, and a high incidence of congenital heart
CC       defects and hypertrophic cardiomyopathy. Other features can include a
CC       short neck with webbing or redundancy of skin, deafness, motor delay,
CC       variable intellectual deficits, multiple skeletal defects,
CC       cryptorchidism, and bleeding diathesis. Individuals with Noonan
CC       syndrome are at risk of juvenile myelomonocytic leukemia, a
CC       myeloproliferative disorder characterized by excessive production of
CC       myelomonocytic cells. {ECO:0000269|PubMed:17603482,
CC       ECO:0000269|PubMed:17603483, ECO:0000269|PubMed:20683980}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: LEOPARD syndrome 2 (LPRD2) [MIM:611554]: A disorder
CC       characterized by lentigines, electrocardiographic conduction
CC       abnormalities, ocular hypertelorism, pulmonic stenosis, abnormalities
CC       of genitalia, retardation of growth, and sensorineural deafness.
CC       {ECO:0000269|PubMed:17603483}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Cardiomyopathy, dilated 1NN (CMD1NN) [MIM:615916]: A disorder
CC       characterized by ventricular dilation and impaired systolic function,
CC       resulting in congestive heart failure and arrhythmia. Patients are at
CC       risk of premature death. {ECO:0000269|PubMed:24777450}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thr
CC       protein kinase family. RAF subfamily. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/raf1/";
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/RAF1ID42032ch3p25.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X03484; CAA27204.1; -; mRNA.
DR   EMBL; AY271661; AAP03432.1; -; Genomic_DNA.
DR   EMBL; AK312248; BAG35180.1; -; mRNA.
DR   EMBL; EU332868; ABY87557.1; -; Genomic_DNA.
DR   EMBL; CH471055; EAW64134.1; -; Genomic_DNA.
DR   EMBL; BC018119; AAH18119.1; -; mRNA.
DR   EMBL; L00212; AAA60247.1; -; Genomic_DNA.
DR   EMBL; L00206; AAA60247.1; JOINED; Genomic_DNA.
DR   EMBL; L00207; AAA60247.1; JOINED; Genomic_DNA.
DR   EMBL; L00208; AAA60247.1; JOINED; Genomic_DNA.
DR   EMBL; L00209; AAA60247.1; JOINED; Genomic_DNA.
DR   EMBL; L00210; AAA60247.1; JOINED; Genomic_DNA.
DR   EMBL; L00211; AAA60247.1; JOINED; Genomic_DNA.
DR   EMBL; L00213; AAA60247.1; JOINED; Genomic_DNA.
DR   EMBL; M11376; AAA60247.1; JOINED; Genomic_DNA.
DR   EMBL; X54851; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   CCDS; CCDS2612.1; -. [P04049-1]
DR   CCDS; CCDS87047.1; -. [P04049-2]
DR   PIR; A00637; TVHUF6.
DR   PIR; S60341; S60341.
DR   RefSeq; NP_002871.1; NM_002880.3. [P04049-1]
DR   RefSeq; XP_005265412.1; XM_005265355.2.
DR   RefSeq; XP_011532276.1; XM_011533974.2. [P04049-1]
DR   PDB; 1C1Y; X-ray; 1.90 A; B=55-131.
DR   PDB; 1FAQ; NMR; -; A=136-187.
DR   PDB; 1FAR; NMR; -; A=136-187.
DR   PDB; 1GUA; X-ray; 2.00 A; B=51-131.
DR   PDB; 1RFA; NMR; -; A=55-132.
DR   PDB; 3CU8; X-ray; 2.40 A; P/Q=256-264.
DR   PDB; 3IQJ; X-ray; 1.15 A; P=255-264.
DR   PDB; 3IQU; X-ray; 1.05 A; P=255-260.
DR   PDB; 3IQV; X-ray; 1.20 A; P=255-260.
DR   PDB; 3KUC; X-ray; 1.92 A; B=51-131.
DR   PDB; 3KUD; X-ray; 2.15 A; B=51-131.
DR   PDB; 3NKX; X-ray; 2.40 A; P/Q=255-264.
DR   PDB; 3O8I; X-ray; 2.00 A; B=255-264.
DR   PDB; 3OMV; X-ray; 4.00 A; A/B=323-618.
DR   PDB; 4FJ3; X-ray; 1.95 A; P=229-264.
DR   PDB; 4G0N; X-ray; 2.45 A; B=54-131.
DR   PDB; 4G3X; X-ray; 3.25 A; B=55-131.
DR   PDB; 4IEA; X-ray; 1.70 A; P=618-625.
DR   PDB; 4IHL; X-ray; 2.20 A; P=229-264.
DR   PDB; 6NTC; X-ray; 2.90 A; B=55-131.
DR   PDB; 6NTD; X-ray; 3.15 A; B=55-131.
DR   PDB; 6PTS; NMR; -; D=56-187.
DR   PDB; 6PTW; NMR; -; D=56-187.
DR   PDB; 6VJJ; X-ray; 1.40 A; B=52-131.
DR   PDB; 6XGU; X-ray; 2.70 A; B=52-188.
DR   PDB; 6XGV; X-ray; 2.11 A; B=52-188.
DR   PDB; 6XHA; X-ray; 2.87 A; B=52-188.
DR   PDB; 6XHB; X-ray; 2.50 A; B=52-188.
DR   PDB; 6XI7; X-ray; 1.95 A; B=52-188.
DR   PDB; 7JHP; X-ray; 2.77 A; C=55-187.
DR   PDBsum; 1C1Y; -.
DR   PDBsum; 1FAQ; -.
DR   PDBsum; 1FAR; -.
DR   PDBsum; 1GUA; -.
DR   PDBsum; 1RFA; -.
DR   PDBsum; 3CU8; -.
DR   PDBsum; 3IQJ; -.
DR   PDBsum; 3IQU; -.
DR   PDBsum; 3IQV; -.
DR   PDBsum; 3KUC; -.
DR   PDBsum; 3KUD; -.
DR   PDBsum; 3NKX; -.
DR   PDBsum; 3O8I; -.
DR   PDBsum; 3OMV; -.
DR   PDBsum; 4FJ3; -.
DR   PDBsum; 4G0N; -.
DR   PDBsum; 4G3X; -.
DR   PDBsum; 4IEA; -.
DR   PDBsum; 4IHL; -.
DR   PDBsum; 6NTC; -.
DR   PDBsum; 6NTD; -.
DR   PDBsum; 6PTS; -.
DR   PDBsum; 6PTW; -.
DR   PDBsum; 6VJJ; -.
DR   PDBsum; 6XGU; -.
DR   PDBsum; 6XGV; -.
DR   PDBsum; 6XHA; -.
DR   PDBsum; 6XHB; -.
DR   PDBsum; 6XI7; -.
DR   PDBsum; 7JHP; -.
DR   AlphaFoldDB; P04049; -.
DR   BMRB; P04049; -.
DR   SMR; P04049; -.
DR   BioGRID; 111831; 323.
DR   CORUM; P04049; -.
DR   DIP; DIP-1048N; -.
DR   IntAct; P04049; 208.
DR   MINT; P04049; -.
DR   STRING; 9606.ENSP00000251849; -.
DR   BindingDB; P04049; -.
DR   ChEMBL; CHEMBL1906; -.
DR   DrugBank; DB08862; Cholecystokinin.
DR   DrugBank; DB08912; Dabrafenib.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugBank; DB05268; iCo-007.
DR   DrugBank; DB04973; LErafAON.
DR   DrugBank; DB08896; Regorafenib.
DR   DrugBank; DB00398; Sorafenib.
DR   DrugBank; DB05190; XL281.
DR   DrugCentral; P04049; -.
DR   GuidetoPHARMACOLOGY; 2184; -.
DR   MoonDB; P04049; Predicted.
DR   GlyGen; P04049; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; P04049; -.
DR   PhosphoSitePlus; P04049; -.
DR   BioMuta; RAF1; -.
DR   DMDM; 125651; -.
DR   CPTAC; CPTAC-1335; -.
DR   CPTAC; CPTAC-1336; -.
DR   CPTAC; CPTAC-1546; -.
DR   CPTAC; CPTAC-1762; -.
DR   EPD; P04049; -.
DR   jPOST; P04049; -.
DR   MassIVE; P04049; -.
DR   MaxQB; P04049; -.
DR   PaxDb; P04049; -.
DR   PeptideAtlas; P04049; -.
DR   PRIDE; P04049; -.
DR   ProteomicsDB; 51637; -. [P04049-1]
DR   ProteomicsDB; 51638; -. [P04049-2]
DR   Antibodypedia; 1131; 3156 antibodies from 49 providers.
DR   CPTC; P04049; 8 antibodies.
DR   DNASU; 5894; -.
DR   Ensembl; ENST00000251849.9; ENSP00000251849.4; ENSG00000132155.14. [P04049-1]
DR   Ensembl; ENST00000442415.7; ENSP00000401888.2; ENSG00000132155.14. [P04049-2]
DR   Ensembl; ENST00000685653.1; ENSP00000509968.1; ENSG00000132155.14. [P04049-1]
DR   Ensembl; ENST00000691899.1; ENSP00000508763.1; ENSG00000132155.14. [P04049-1]
DR   GeneID; 5894; -.
DR   KEGG; hsa:5894; -.
DR   MANE-Select; ENST00000251849.9; ENSP00000251849.4; NM_002880.4; NP_002871.1.
DR   UCSC; uc003bxf.5; human. [P04049-1]
DR   CTD; 5894; -.
DR   DisGeNET; 5894; -.
DR   GeneCards; RAF1; -.
DR   GeneReviews; RAF1; -.
DR   HGNC; HGNC:9829; RAF1.
DR   HPA; ENSG00000132155; Low tissue specificity.
DR   MalaCards; RAF1; -.
DR   MIM; 164760; gene.
DR   MIM; 611553; phenotype.
DR   MIM; 611554; phenotype.
DR   MIM; 615916; phenotype.
DR   neXtProt; NX_P04049; -.
DR   OpenTargets; ENSG00000132155; -.
DR   Orphanet; 154; Familial isolated dilated cardiomyopathy.
DR   Orphanet; 648; Noonan syndrome.
DR   Orphanet; 500; Noonan syndrome with multiple lentigines.
DR   Orphanet; 251615; Pilomyxoid astrocytoma.
DR   PharmGKB; PA34183; -.
DR   VEuPathDB; HostDB:ENSG00000132155; -.
DR   eggNOG; KOG0193; Eukaryota.
DR   GeneTree; ENSGT00940000156084; -.
DR   InParanoid; P04049; -.
DR   OMA; SWCHRFW; -.
DR   OrthoDB; 243095at2759; -.
DR   PhylomeDB; P04049; -.
DR   TreeFam; TF317006; -.
DR   BRENDA; 2.7.10.2; 2681.
DR   PathwayCommons; P04049; -.
DR   Reactome; R-HSA-2672351; Stimuli-sensing channels.
DR   Reactome; R-HSA-392517; Rap1 signalling.
DR   Reactome; R-HSA-430116; GP1b-IX-V activation signalling.
DR   Reactome; R-HSA-5621575; CD209 (DC-SIGN) signaling.
DR   Reactome; R-HSA-5673000; RAF activation.
DR   Reactome; R-HSA-5674135; MAP2K and MAPK activation.
DR   Reactome; R-HSA-5674499; Negative feedback regulation of MAPK pathway.
DR   Reactome; R-HSA-5675221; Negative regulation of MAPK pathway.
DR   Reactome; R-HSA-6802946; Signaling by moderate kinase activity BRAF mutants.
DR   Reactome; R-HSA-6802948; Signaling by high-kinase activity BRAF mutants.
DR   Reactome; R-HSA-6802952; Signaling by BRAF and RAF1 fusions.
DR   Reactome; R-HSA-6802955; Paradoxical activation of RAF signaling by kinase inactive BRAF.
DR   Reactome; R-HSA-9649948; Signaling downstream of RAS mutants.
DR   Reactome; R-HSA-9656223; Signaling by RAF1 mutants.
DR   Reactome; R-HSA-9726840; SHOC2 M1731 mutant abolishes MRAS complex function.
DR   Reactome; R-HSA-9726842; Gain-of-function MRAS complexes activate RAF signaling.
DR   SignaLink; P04049; -.
DR   SIGNOR; P04049; -.
DR   BioGRID-ORCS; 5894; 93 hits in 1120 CRISPR screens.
DR   ChiTaRS; RAF1; human.
DR   EvolutionaryTrace; P04049; -.
DR   GeneWiki; C-Raf; -.
DR   GenomeRNAi; 5894; -.
DR   Pharos; P04049; Tclin.
DR   PRO; PR:P04049; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   RNAct; P04049; protein.
DR   Bgee; ENSG00000132155; Expressed in gastrocnemius and 212 other tissues.
DR   ExpressionAtlas; P04049; baseline and differential.
DR   Genevisible; P04049; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:MGI.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0005794; C:Golgi apparatus; IPI:MGI.
DR   GO; GO:0005741; C:mitochondrial outer membrane; TAS:ProtInc.
DR   GO; GO:0005739; C:mitochondrion; IBA:GO_Central.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0031143; C:pseudopodium; IEA:Ensembl.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0019899; F:enzyme binding; IPI:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0004709; F:MAP kinase kinase kinase activity; IBA:GO_Central.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0004672; F:protein kinase activity; TAS:ProtInc.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0007190; P:activation of adenylate cyclase activity; IDA:BHF-UCL.
DR   GO; GO:0006915; P:apoptotic process; TAS:GO_Central.
DR   GO; GO:0030154; P:cell differentiation; IEA:Ensembl.
DR   GO; GO:0071550; P:death-inducing signaling complex assembly; IEA:Ensembl.
DR   GO; GO:0008625; P:extrinsic apoptotic signaling pathway via death domain receptors; IEA:Ensembl.
DR   GO; GO:0060324; P:face development; IEA:Ensembl.
DR   GO; GO:0035773; P:insulin secretion involved in cellular response to glucose stimulus; IEA:Ensembl.
DR   GO; GO:0045104; P:intermediate filament cytoskeleton organization; IEA:Ensembl.
DR   GO; GO:0000165; P:MAPK cascade; IBA:GO_Central.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IDA:UniProtKB.
DR   GO; GO:0008285; P:negative regulation of cell population proliferation; IDA:BHF-UCL.
DR   GO; GO:0043154; P:negative regulation of cysteine-type endopeptidase activity involved in apoptotic process; TAS:UniProtKB.
DR   GO; GO:1902042; P:negative regulation of extrinsic apoptotic signaling pathway via death domain receptors; IEA:Ensembl.
DR   GO; GO:0031333; P:negative regulation of protein-containing complex assembly; IDA:UniProtKB.
DR   GO; GO:0048011; P:neurotrophin TRK receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; IDA:GO_Central.
DR   GO; GO:0033138; P:positive regulation of peptidyl-serine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IEA:Ensembl.
DR   GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc.
DR   GO; GO:0042981; P:regulation of apoptotic process; TAS:UniProtKB.
DR   GO; GO:0045595; P:regulation of cell differentiation; TAS:UniProtKB.
DR   GO; GO:2000145; P:regulation of cell motility; TAS:UniProtKB.
DR   GO; GO:0035023; P:regulation of Rho protein signal transduction; TAS:UniProtKB.
DR   GO; GO:0035994; P:response to muscle stretch; IEA:Ensembl.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0035019; P:somatic stem cell population maintenance; IEA:Ensembl.
DR   GO; GO:0048538; P:thymus development; IEA:Ensembl.
DR   GO; GO:0030878; P:thyroid gland development; IEA:Ensembl.
DR   GO; GO:0042060; P:wound healing; TAS:UniProtKB.
DR   CDD; cd00029; C1; 1.
DR   IDEAL; IID00292; -.
DR   InterPro; IPR046349; C1-like_sf.
DR   InterPro; IPR020454; DAG/PE-bd.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR002219; PE/DAG-bd.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR003116; RBD_dom.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   InterPro; IPR029071; Ubiquitin-like_domsf.
DR   Pfam; PF00130; C1_1; 1.
DR   Pfam; PF07714; PK_Tyr_Ser-Thr; 1.
DR   Pfam; PF02196; RBD; 1.
DR   PRINTS; PR00008; DAGPEDOMAIN.
DR   SMART; SM00109; C1; 1.
DR   SMART; SM00455; RBD; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF54236; SSF54236; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   SUPFAM; SSF57889; SSF57889; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
DR   PROSITE; PS50898; RBD; 1.
DR   PROSITE; PS00479; ZF_DAG_PE_1; 1.
DR   PROSITE; PS50081; ZF_DAG_PE_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cardiomyopathy;
KW   Cell membrane; Cytoplasm; Deafness; Direct protein sequencing;
KW   Disease variant; Kinase; Membrane; Metal-binding; Methylation;
KW   Mitochondrion; Nucleotide-binding; Nucleus; Phosphoprotein; Proto-oncogene;
KW   Reference proteome; Serine/threonine-protein kinase; Transferase; Zinc;
KW   Zinc-finger.
FT   CHAIN           1..648
FT                   /note="RAF proto-oncogene serine/threonine-protein kinase"
FT                   /id="PRO_0000086596"
FT   DOMAIN          56..131
FT                   /note="RBD"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00262"
FT   DOMAIN          349..609
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   ZN_FING         138..184
FT                   /note="Phorbol-ester/DAG-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00226"
FT   REGION          220..334
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          331..349
FT                   /note="Interaction with PEBP1/RKIP"
FT   COMPBIAS        222..269
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        284..310
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        468
FT                   /note="Proton acceptor"
FT   BINDING         139
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT   BINDING         152
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="2"
FT   BINDING         155
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="2"
FT   BINDING         165
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT   BINDING         168
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT   BINDING         173
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="2"
FT   BINDING         176
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="2"
FT   BINDING         184
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT   BINDING         355..363
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         375
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         29
FT                   /note="Phosphoserine; by MAPK1"
FT                   /evidence="ECO:0000250|UniProtKB:Q99N57"
FT   MOD_RES         43
FT                   /note="Phosphoserine; by PKA and MAPK1"
FT                   /evidence="ECO:0000269|PubMed:8349614"
FT   MOD_RES         252
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17525332"
FT   MOD_RES         259
FT                   /note="Phosphoserine; by PKA, PKC and PKB/AKT1"
FT                   /evidence="ECO:0000269|PubMed:10576742,
FT                   ECO:0000269|PubMed:10801873, ECO:0000269|PubMed:11756411,
FT                   ECO:0000269|PubMed:15047712, ECO:0000269|PubMed:16630891,
FT                   ECO:0000269|PubMed:16892053, ECO:0000269|PubMed:8349614"
FT   MOD_RES         268
FT                   /note="Phosphothreonine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:8349614"
FT   MOD_RES         269
FT                   /note="Phosphothreonine; by PKA"
FT                   /evidence="ECO:0000269|PubMed:7477354"
FT   MOD_RES         289
FT                   /note="Phosphoserine; by MAPK1"
FT                   /evidence="ECO:0000269|PubMed:21917714,
FT                   ECO:0007744|PubMed:19690332"
FT   MOD_RES         296
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         301
FT                   /note="Phosphoserine; by MAPK1"
FT                   /evidence="ECO:0000269|PubMed:21917714,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:23186163"
FT   MOD_RES         338
FT                   /note="Phosphoserine; by PAK1, PAK2, PAK3 and PAK5"
FT                   /evidence="ECO:0000269|PubMed:11733498,
FT                   ECO:0000269|PubMed:15849194, ECO:0000269|PubMed:16892053,
FT                   ECO:0000269|PubMed:18465753, ECO:0000269|PubMed:21917714"
FT   MOD_RES         339
FT                   /note="Phosphoserine; by PAK1, PAK2 and PAK3"
FT                   /evidence="ECO:0000269|PubMed:15849194"
FT   MOD_RES         340
FT                   /note="Phosphotyrosine; by SRC"
FT                   /evidence="ECO:0000269|PubMed:16892053"
FT   MOD_RES         341
FT                   /note="Phosphotyrosine; by SRC"
FT                   /evidence="ECO:0000269|PubMed:16892053"
FT   MOD_RES         471
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:16093354"
FT   MOD_RES         491
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000269|PubMed:11447113"
FT   MOD_RES         494
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:11447113"
FT   MOD_RES         499
FT                   /note="Phosphoserine; by PKC"
FT                   /evidence="ECO:0000269|PubMed:8349614"
FT   MOD_RES         563
FT                   /note="Symmetric dimethylarginine; by PRMT5"
FT                   /evidence="ECO:0000269|PubMed:21917714"
FT   MOD_RES         621
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:10801873,
FT                   ECO:0000269|PubMed:16892053, ECO:0000269|PubMed:21917714,
FT                   ECO:0000269|PubMed:8349614"
FT   MOD_RES         642
FT                   /note="Phosphoserine; by MAPK1"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:23186163"
FT   VAR_SEQ         278
FT                   /note="E -> ENNNLSASPRAWSRRFCLRGR (in isoform 2)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_034649"
FT   VARIANT         237
FT                   /note="A -> T (in CMD1NN; shows a mild increase in kinase
FT                   activity; dbSNP:rs587777588)"
FT                   /evidence="ECO:0000269|PubMed:24777450"
FT                   /id="VAR_071844"
FT   VARIANT         256
FT                   /note="R -> S (in NS5; dbSNP:rs397516826)"
FT                   /evidence="ECO:0000269|PubMed:17603483"
FT                   /id="VAR_037807"
FT   VARIANT         257
FT                   /note="S -> L (in NS5 and LPRD2; shows in vitro greater
FT                   kinase activity and enhanced ERK activation than wild-type;
FT                   dbSNP:rs80338796)"
FT                   /evidence="ECO:0000269|PubMed:17603482,
FT                   ECO:0000269|PubMed:17603483"
FT                   /id="VAR_037808"
FT   VARIANT         259
FT                   /note="S -> A (in an ovarian serous carcinoma sample;
FT                   somatic mutation; increased ERK activation;
FT                   dbSNP:rs3730271)"
FT                   /evidence="ECO:0000269|PubMed:16630891,
FT                   ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041037"
FT   VARIANT         259
FT                   /note="S -> F (in NS5; dbSNP:rs397516827)"
FT                   /evidence="ECO:0000269|PubMed:17603483"
FT                   /id="VAR_037809"
FT   VARIANT         260
FT                   /note="T -> I (in hypertrophic cardiomyopathy; unknown
FT                   pathological significance; dbSNP:rs869025501)"
FT                   /evidence="ECO:0000269|PubMed:17603483"
FT                   /id="VAR_037810"
FT   VARIANT         260
FT                   /note="T -> R (in NS5)"
FT                   /evidence="ECO:0000269|PubMed:17603483"
FT                   /id="VAR_037811"
FT   VARIANT         261
FT                   /note="P -> A (in NS5; shows in vitro greater kinase
FT                   activity and enhanced MAPK1 activation than wild-type;
FT                   dbSNP:rs121434594)"
FT                   /evidence="ECO:0000269|PubMed:17603482"
FT                   /id="VAR_037812"
FT   VARIANT         261
FT                   /note="P -> L (in NS5; shows greater kinase activity and
FT                   enhanced MAPK1 activation than wild-type;
FT                   dbSNP:rs397516828)"
FT                   /evidence="ECO:0000269|PubMed:17603483"
FT                   /id="VAR_037813"
FT   VARIANT         261
FT                   /note="P -> S (in NS5; shows in vitro greater kinase
FT                   activity and enhanced MAPK1 activation than wild-type;
FT                   dbSNP:rs121434594)"
FT                   /evidence="ECO:0000269|PubMed:17603482,
FT                   ECO:0000269|PubMed:17603483, ECO:0000269|PubMed:20683980"
FT                   /id="VAR_037814"
FT   VARIANT         263
FT                   /note="V -> A (in NS5; shows in vitro greater kinase
FT                   activity and enhanced MAPK1 activation than wild-type;
FT                   dbSNP:rs397516830)"
FT                   /evidence="ECO:0000269|PubMed:17603482"
FT                   /id="VAR_037815"
FT   VARIANT         308
FT                   /note="P -> L (in dbSNP:rs5746220)"
FT                   /evidence="ECO:0000269|PubMed:14702039, ECO:0000269|Ref.3"
FT                   /id="VAR_018840"
FT   VARIANT         310
FT                   /note="T -> A (in CMD1NN; shows a mild increase in kinase
FT                   activity; dbSNP:rs778155315)"
FT                   /evidence="ECO:0000269|PubMed:24777450"
FT                   /id="VAR_071845"
FT   VARIANT         332
FT                   /note="P -> A (in CMD1NN; shows a mild increase in kinase
FT                   activity; dbSNP:rs1057403865)"
FT                   /evidence="ECO:0000269|PubMed:24777450"
FT                   /id="VAR_071846"
FT   VARIANT         335
FT                   /note="Q -> H (in a lung adenocarcinoma sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041038"
FT   VARIANT         486
FT                   /note="D -> G (in NS5; dbSNP:rs397516815)"
FT                   /evidence="ECO:0000269|PubMed:17603483"
FT                   /id="VAR_037816"
FT   VARIANT         486
FT                   /note="D -> N (in NS5; has reduced or absent kinase
FT                   activity; dbSNP:rs80338798)"
FT                   /evidence="ECO:0000269|PubMed:17603483"
FT                   /id="VAR_037817"
FT   VARIANT         491
FT                   /note="T -> I (in NS5; has reduced or absent kinase
FT                   activity; dbSNP:rs80338799)"
FT                   /evidence="ECO:0000269|PubMed:17603483"
FT                   /id="VAR_037818"
FT   VARIANT         491
FT                   /note="T -> R (in NS5; dbSNP:rs80338799)"
FT                   /evidence="ECO:0000269|PubMed:17603483"
FT                   /id="VAR_037819"
FT   VARIANT         603
FT                   /note="L -> P (in CMD1NN; shows impaired kinase activity
FT                   and reduced MAPK3 activation with this mutation;
FT                   dbSNP:rs587777586)"
FT                   /evidence="ECO:0000269|PubMed:24777450"
FT                   /id="VAR_071847"
FT   VARIANT         612
FT                   /note="S -> T (in NS5; dbSNP:rs1448392469)"
FT                   /evidence="ECO:0000269|PubMed:17603483"
FT                   /id="VAR_037820"
FT   VARIANT         613
FT                   /note="L -> V (in NS5 and LPRD2; shows in vitro greater
FT                   kinase activity and enhanced MAPK1 activation than
FT                   wild-type; dbSNP:rs80338797)"
FT                   /evidence="ECO:0000269|PubMed:17603482,
FT                   ECO:0000269|PubMed:17603483"
FT                   /id="VAR_037821"
FT   VARIANT         626
FT                   /note="H -> R (in CMD1NN; shows a mild increase in kinase
FT                   activity; dbSNP:rs1553609795)"
FT                   /evidence="ECO:0000269|PubMed:24777450"
FT                   /id="VAR_071848"
FT   VARIANT         641
FT                   /note="T -> M (in CMD1NN; shows a mild increase in kinase
FT                   activity; dbSNP:rs587777587)"
FT                   /evidence="ECO:0000269|PubMed:24777450"
FT                   /id="VAR_071849"
FT   MUTAGEN         338..339
FT                   /note="SS->AA: Reduced kinase activity; when associated
FT                   with 340-D-D-341."
FT                   /evidence="ECO:0000269|PubMed:16892053"
FT   MUTAGEN         338..339
FT                   /note="SS->DE: Non-inhibited by PPP5C. Constitutively
FT                   active and non-inhibited by PPP5C; when associated with
FT                   340-D-D-341."
FT                   /evidence="ECO:0000269|PubMed:16892053"
FT   MUTAGEN         340..341
FT                   /note="YY->DD: Constitutively active and highly
FT                   phosphorylated on S-338, inhibited by PPP5C. Reduced kinase
FT                   activity; when associated with 338-A-A-339. Constitutively
FT                   active and non-inhibited by PPP5C; when associated with
FT                   338-D-E-339."
FT                   /evidence="ECO:0000269|PubMed:16892053"
FT   MUTAGEN         375
FT                   /note="K->W: Catalytically inactive."
FT                   /evidence="ECO:0000269|PubMed:20956560"
FT   MUTAGEN         491
FT                   /note="T->D: Increased kinase activity but can still be
FT                   inhibited by PPP5C; when associated with D-494."
FT                   /evidence="ECO:0000269|PubMed:16892053"
FT   MUTAGEN         494
FT                   /note="S->D: Increased kinase activity but can still be
FT                   inhibited by PPP5C; when associated with D-491."
FT                   /evidence="ECO:0000269|PubMed:16892053"
FT   MUTAGEN         563
FT                   /note="R->K: Loss of methylation. Increased stability and
FT                   catalytic activity in response to EGF treatment."
FT                   /evidence="ECO:0000269|PubMed:21917714"
FT   CONFLICT        240
FT                   /note="F -> L (in Ref. 6; AAA60247)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        542
FT                   /note="M -> I (in Ref. 6; AAA60247)"
FT                   /evidence="ECO:0000305"
FT   STRAND          57..61
FT                   /evidence="ECO:0007829|PDB:6VJJ"
FT   TURN            63..65
FT                   /evidence="ECO:0007829|PDB:1C1Y"
FT   STRAND          67..71
FT                   /evidence="ECO:0007829|PDB:6VJJ"
FT   HELIX           78..88
FT                   /evidence="ECO:0007829|PDB:6VJJ"
FT   HELIX           93..95
FT                   /evidence="ECO:0007829|PDB:6VJJ"
FT   STRAND          96..100
FT                   /evidence="ECO:0007829|PDB:6VJJ"
FT   STRAND          103..107
FT                   /evidence="ECO:0007829|PDB:6VJJ"
FT   STRAND          109..112
FT                   /evidence="ECO:0007829|PDB:3KUC"
FT   HELIX           118..121
FT                   /evidence="ECO:0007829|PDB:6VJJ"
FT   STRAND          125..130
FT                   /evidence="ECO:0007829|PDB:6VJJ"
FT   STRAND          132..134
FT                   /evidence="ECO:0007829|PDB:6PTW"
FT   STRAND          135..137
FT                   /evidence="ECO:0007829|PDB:6XGV"
FT   STRAND          141..145
FT                   /evidence="ECO:0007829|PDB:6XI7"
FT   TURN            153..155
FT                   /evidence="ECO:0007829|PDB:6XI7"
FT   STRAND          160..165
FT                   /evidence="ECO:0007829|PDB:6XI7"
FT   TURN            166..168
FT                   /evidence="ECO:0007829|PDB:6XI7"
FT   STRAND          170..172
FT                   /evidence="ECO:0007829|PDB:7JHP"
FT   HELIX           174..179
FT                   /evidence="ECO:0007829|PDB:6XI7"
FT   STRAND          182..185
FT                   /evidence="ECO:0007829|PDB:6XGV"
SQ   SEQUENCE   648 AA;  73052 MW;  EF821B5349711BC3 CRC64;
     MEHIQGAWKT ISNGFGFKDA VFDGSSCISP TIVQQFGYQR RASDDGKLTD PSKTSNTIRV
     FLPNKQRTVV NVRNGMSLHD CLMKALKVRG LQPECCAVFR LLHEHKGKKA RLDWNTDAAS
     LIGEELQVDF LDHVPLTTHN FARKTFLKLA FCDICQKFLL NGFRCQTCGY KFHEHCSTKV
     PTMCVDWSNI RQLLLFPNST IGDSGVPALP SLTMRRMRES VSRMPVSSQH RYSTPHAFTF
     NTSSPSSEGS LSQRQRSTST PNVHMVSTTL PVDSRMIEDA IRSHSESASP SALSSSPNNL
     SPTGWSQPKT PVPAQRERAP VSGTQEKNKI RPRGQRDSSY YWEIEASEVM LSTRIGSGSF
     GTVYKGKWHG DVAVKILKVV DPTPEQFQAF RNEVAVLRKT RHVNILLFMG YMTKDNLAIV
     TQWCEGSSLY KHLHVQETKF QMFQLIDIAR QTAQGMDYLH AKNIIHRDMK SNNIFLHEGL
     TVKIGDFGLA TVKSRWSGSQ QVEQPTGSVL WMAPEVIRMQ DNNPFSFQSD VYSYGIVLYE
     LMTGELPYSH INNRDQIIFM VGRGYASPDL SKLYKNCPKA MKRLVADCVK KVKEERPLFP
     QILSSIELLQ HSLPKINRSA SEPSLHRAAH TEDINACTLT TSPRLPVF
//
